Results 261 to 270 of about 332,330 (302)

Pathophysiology of Graft-Versus-Host Disease

Seminars in Hematology, 2006
Complications of allogeneic hematopoietic stem cell transplantation (HSCT) remain barriers to its wider application for a variety of diseases. Graft-versus-host disease (GVHD) is the major cause of morbidity and mortality following allogeneic HSCT. GVHD can be considered an exaggerated, undesirable manifestation of a normal inflammatory mechanism, in ...
James L M, Ferrara, Pavan, Reddy
openaire   +2 more sources

Chronic Graft-Versus-Host Disease

Oncology Nursing Forum, 2006
Chronic graft versus host disease is a debilitating and often fatal complication of allogeneic stem cell transplantation. The purpose of this review is to overview this disease and highlight recent findings in the literature over the past year.A new focus on chronic graft versus host disease as a long-term complication of transplantation has resulted ...
Ellaine, Galbizo, Lori A, Williams
openaire   +4 more sources

Management of graft-versus-host disease

Transfusion Science, 1994
Allogeneic bone marrow transplantation (BMT) involves transfer of primitive multipotential lymphohematopoietic stem cells from donor to recipient. In clinical transplantation, however, the aspirated marrow also contains substantial numbers of viable lymphoid cells, some originating from the marrow and some inadvertently collected by contamination of ...
openaire   +2 more sources

Review of Graft-Versus-Host Disease

Dermatologic Clinics, 2019
Graft-versus-host disease (GVHD) is an adverse immunologic phenomenon following allogenic hematopoietic stem cell transplant. Cutaneous manifestations are the earliest and most common presentation of the disease. This article describes the pathophysiology, clinical presentation, diagnosis, and treatment options available for acute and chronic GVHD ...
Vignesh, Ramachandran, Sree S, Kolli, Lindsay C, Strowd   +2 more
openaire   +2 more sources

History of graft-versus-host disease

Experimental Hematology, 2016
Nuclear warfare at the end of World War II inspired Dick W. van Bekkum to study total-body irradiation (TBI) in animal models. After high-dose TBI, mice died from "primary disease" or bone marrow (BM) aplasia. Intravenous administration of allogeneic BM cells delayed mortality but did not prevent it.
Huib M, Vriesendorp, Peter J, Heidt
openaire   +2 more sources

Chronic Graft-Versus-Host Disease

Journal of Hematotherapy & Stem Cell Research, 2000
bidity following BMT is graft-versus-host disease (GVHD). In several large recent trials, 40‐ 60% of patients surviving more than 100 days have developed chronic GVHD (1‐ 3). The incidence of chronic GVHD is expected to rise due to several trends in transplantation.
J, Margolis, G, Vogelsang
openaire   +2 more sources

Predicting graft-versus-host disease

Current Opinion in Immunology, 1995
Graft-versus-host disease (GVHD) is a serious complication that occurs after allogeneic bone marrow transplantation and contributes to transplant-related morbidity and mortality. Recent advances in the measurement of recipient-specific alloreactivity before marrow grafting have led to the development of in vitro assays that sufficiently predict the ...
openaire   +2 more sources

Graft-versus-host disease and phimosis

Journal of Pediatric Urology, 2008
Graft-versus-host disease rarely causes genitourinary problems. We report a case of pathological phimosis in a child secondary to chronic graft-versus-host disease.
S T, Patel, M N, Woodward, M, Williams, M, O'Brien, H, Chandran, K, Parashar   +5 more
openaire   +2 more sources

Graft-Versus-Host Disease: Implications

1993
The intent of the preparative regimen for bone marrow transplantation (BMT) is the destruction of the host tumor cell and the complete ablation of the host lymphohematopoietic system (Thomas 1983). Most aggressive conditioning regimens are applied, usually combining chemo- and radiotherapy, the latter in the form of total body irradiation.
openaire   +2 more sources

Graft-versus-host disease and immunosuppression

Immunologic Research, 2008
In the last four decades, allogeneic hematopoietic stem cell transplant (HSCT) has been established as a curative therapy for many otherwise fatal diseases. Since 1968, from the time of the first successful allogeneic bone marrow transplant in a child with severe combined immune deficiency disease [1], tremendous progress has been made in this field of
openaire   +2 more sources